{"id":"peginterferon-alfa-2a-40kd-and-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-20","effect":"Hemolytic anemia"},{"rate":"5-15","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression and neuropsychiatric effects"},{"rate":"5-10","effect":"Thyroid dysfunction"},{"rate":"20-30","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201560","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peginterferon alfa-2a is a long-acting interferon that binds to type I interferon receptors, triggering JAK-STAT signaling to induce antiviral and immunomodulatory responses. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and may enhance T-cell responses. Together, this combination was the standard-of-care treatment for chronic hepatitis C before direct-acting antivirals became available.","oneSentence":"Peginterferon alfa-2a activates interferon-alpha receptors to enhance antiviral immunity, while ribavirin inhibits viral RNA synthesis, together suppressing hepatitis C virus replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:57.469Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype-dependent, now largely superseded by direct-acting antivirals)"}]},"trialDetails":[{"nctId":"NCT00087633","phase":"PHASE4","title":"PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Hepatitis C, Chronic","enrollment":115},{"nctId":"NCT01416610","phase":"","title":"An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-04","conditions":"Hepatitis C, Chronic","enrollment":88},{"nctId":"NCT01591460","phase":"PHASE4","title":"A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-08","conditions":"Hepatitis C, Chronic","enrollment":165},{"nctId":"NCT00475072","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-06","conditions":"Hepatitis C, Chronic","enrollment":14},{"nctId":"NCT01464008","phase":"","title":"The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C","status":"COMPLETED","sponsor":"Beijing Ditan Hospital","startDate":"2004-01","conditions":"Chronic Hepatitis C","enrollment":297},{"nctId":"NCT02716779","phase":"PHASE2","title":"Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Hepatitis C, Chronic","enrollment":68},{"nctId":"NCT00087607","phase":"PHASE4","title":"Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Hepatitis C, Chronic","enrollment":385},{"nctId":"NCT00107653","phase":"PHASE4","title":"Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Hepatitis C, Chronic","enrollment":569},{"nctId":"NCT00700401","phase":"","title":"POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11","conditions":"Hepatitis C, Chronic","enrollment":262},{"nctId":"NCT00087568","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-01","conditions":"Hepatitis C, Chronic","enrollment":57},{"nctId":"NCT00077649","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Hepatitis C, Chronic","enrollment":188},{"nctId":"NCT00412334","phase":"PHASE4","title":"SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-01","conditions":"Hepatitis C, Chronic","enrollment":104},{"nctId":"NCT00087594","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-11","conditions":"Hepatitis C, Chronic","enrollment":48},{"nctId":"NCT00077636","phase":"PHASE4","title":"ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-12","conditions":"Hepatitis C, Chronic","enrollment":1469},{"nctId":"NCT00922779","phase":"PHASE4","title":"A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-06","conditions":"Hepatitis C, Chronic","enrollment":6661},{"nctId":"NCT00087646","phase":"PHASE4","title":"REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-09","conditions":"Hepatitis C, Chronic","enrollment":948},{"nctId":"NCT01581398","phase":"PHASE3","title":"Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2012-04","conditions":"Chronic Hepatitis C","enrollment":770},{"nctId":"NCT00623428","phase":"PHASE3","title":"A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"Hepatitis C, Chronic","enrollment":235},{"nctId":"NCT00545233","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":155},{"nctId":"NCT00707850","phase":"PHASE4","title":"Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Baqiyatallah Medical Sciences University","startDate":"2007-05","conditions":"Hepatitis C, Thalassemia","enrollment":300},{"nctId":"NCT00353418","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-06","conditions":"Hepatitis C, Chronic","enrollment":415},{"nctId":"NCT00394277","phase":"PHASE4","title":"A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-02","conditions":"Hepatitis C, Chronic","enrollment":1175},{"nctId":"NCT00707772","phase":"PHASE4","title":"Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Baqiyatallah Medical Sciences University","startDate":"2007-03","conditions":"Hepatitis C, Hemophilia","enrollment":400},{"nctId":"NCT00143000","phase":"PHASE4","title":"Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3","status":"COMPLETED","sponsor":"NORDynamIC Study Group","startDate":"2004-04","conditions":"Hepatitis C Virus","enrollment":392}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Peginterferon alfa-2a 40KD and Ribavirin","genericName":"Peginterferon alfa-2a 40KD and Ribavirin","companyName":"NORDynamIC Study Group","companyId":"nordynamic-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peginterferon alfa-2a activates interferon-alpha receptors to enhance antiviral immunity, while ribavirin inhibits viral RNA synthesis, together suppressing hepatitis C virus replication. Used for Chronic hepatitis C virus infection (genotype-dependent, now largely superseded by direct-acting antivirals).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}